Around 30% of all women have ovulatory issues that are undetectable at home and often missed by doctors. Medical advice in the first one to two years is to ‘keep trying’. This makes the problem worse for any woman with an ovulatory issue, as increasing age rapidly reduces the chances of getting pregnant. As a result, over 50% of all women are unable to conceive within 12 months.
Unlike existing fertility predictor systems, OvuSenseTM solves this problem by offering real-time ovulation monitoring. OvuSense helps women manage their cycles and detect if they have ovulatory issues. Crucially it puts women back in control of the conception process.
Fertility Focus is seeking £275,000 in this round for a 6.32% equity stake, with investors being invited to invest a minimum of £1000 at £25 per share.
The company predicts an exit value that could offer investors in this round a potential return worth ten times their investment. Fertility Focus Chairman, Steve Godber, said: “It is not a matter of whether Fertility Focus will deliver a return to shareholders, it is just a question of when and how much.”
The investment could significantly benefit the 24 million women worldwide seeking online advice for fertility problems, such as those caused by polycystic ovarian syndrome (PCOS).
OvuSense is already on the market in Europe and the USA with all the necessary regulatory approvals. It has five clinical publications and a portfolio of six patents that protect its compelling competitive advantages.
The additional investment will enable Fertility Focus to accelerate the launch of its next generation OvuSense product at a much lower price point and extend international sales and marketing for its powerful multi-language, multi-currency e-commerce platform.
Targeted digital marketing is already driving 9,000 new visitors a month to the OvuSense website. The extra investment is intended to boost visitor rates twentyfold and convert 300% more visits to sales via a more affordable monthly subscription model, in turn allowing rapid margin and EBIT growth.
Commenting, Goncalo De Vasconcelos, CEO at SyndicateRoom said: “This is a rare opportunity to invest in a proven product with strong sales traction and a robust global growth strategy. The team has world-class expertise in consumer digital marketing, high-volume medical devices, women’s health and intellectual property development. The CEO, chairman and lead angel investor each have several successful sector exits behind them.”
This funding round for Fertility Focus will close at midnight this Sunday (5 July).
For more please go to www.syndicateroom.com/fertilityfocus
For more about Fertility Focus and OvuSense go to: http://www.fertility-focus.com
NOTES
· The average first-time mother in the UK is 30, exactly when fertility starts to decline, reducing more rapidly after 35, so delayed ovulation detection can exacerbate problems
· Using body temperature monitoring, OvuSense is clinically proven as 99% effective at predicting ovulation a day in advance and confirming that it has definitely occurred
· Conventional over-the-counter ovulation predictor kits are based on hormone detection but do not confirm whether or exactly when ovulation occurs. In some circumstances (eg for women aged 40+) they deliver inconsistent results and ‘false positives’
· OvuSense currently costs £295 for a one-off upfront payment, but the next generation model will be available to try out for one month for an initial £35 and thereafter on a subscription basis
· One round of IVF treatment costs from £7000 in the UK and around $12,000 in the USA.
About SyndicateRoom
Online equity crowdfunding company SyndicateRoom manages a novel investment platform enabling individuals to co-invest in high quality ventures and innovative technologies on the same financial terms as seasoned investors and business angels. Since its first deal went live in 2013, the company has helped raise more than £24million to support UK businesses and start-ups. It has become one of the top three players in the equity crowdfunding market, making it the sector’s fastest growing platform. To date, 80% of companies listing on SyndicateRoom raise the funds they need and 100% are still trading. Successes include the first equity crowdfunded IPO, first equity crowdfunded Hollywood film and the industry’s first ISA investments. The company is based in Cambridge and London.
For more information: www.syndicateroom.com
*******
Media contact for more information: Theresa Prevost, tel 07771 620783 / email [email protected]
____________________________________________
SyndicateRoom delivers fertile growth opportunity to investors
30 June 2015
Equity crowdfunding experts at SyndicateRoom are offering investors a stake in Fertility Focus, the UK company behind an innovative home test device that delivers unprecedented 99% accuracy to help them to conceive.